Partin A W, Catalona W J, Southwick P C, Subong E N, Gasior G H, Chan D W
Department of Urology, Johns Hopkins Hospital, Baltimore, Maryland, USA.
Urology. 1996 Dec;48(6A Suppl):55-61. doi: 10.1016/s0090-4295(96)00611-5.
To determine whether the use of the free-to-total PSA ratio (percent free PSA) could increase the specificity of PSA testing for prostate cancer detection in men with serum PSA concentrations between 4.0 and 10.0 ng/mL, and to assess the influence of total PSA, prostate volume, and age on percent free PSA.
Sera were obtained from 217 men with histologically confirmed diagnoses (139 prostate cancer, 78 benign). Free and total PSA concentrations were determined using Hybritech Tandem assays.
Use of percent free PSA increased PSA specificity: 29% of negative biopsies would be spared while retaining 95% sensitivity. Percent free PSA increased with increasing age and prostate volume. Percent free PSA decreased as total PSA increased. A significant relation exists between percent free PSA and the probability of a positive biopsy; in this cohort, a patient with a low percent free PSA (< or = 10%) had a higher probability of cancer (63 +/- 9%) than a patient with a high percent free PSA (> or = 26%) (probability 2 +/- 3%).
Percent free PSA may be used as an aid in distinguishing prostate cancer from benign disease in men with a total PSA between 4.0 and 10.0 ng/mL. Large prospective multicenter trials are required to develop consistent recommendations and determine the appropriate cutpoints and risk probabilities, controlling for total PSA, prostate volume, age, and biopsy history.
确定使用游离前列腺特异抗原与总前列腺特异抗原比值(游离前列腺特异抗原百分比)是否能提高血清前列腺特异抗原浓度在4.0至10.0 ng/mL之间男性前列腺癌检测中前列腺特异抗原检测的特异性,并评估总前列腺特异抗原、前列腺体积和年龄对游离前列腺特异抗原百分比的影响。
从217名经组织学确诊的男性(139例前列腺癌,78例良性)获取血清。使用Hybritech串联检测法测定游离和总前列腺特异抗原浓度。
使用游离前列腺特异抗原百分比提高了前列腺特异抗原的特异性:29%的阴性活检可避免,同时保持95%的敏感性。游离前列腺特异抗原百分比随年龄和前列腺体积增加而升高。游离前列腺特异抗原百分比随总前列腺特异抗原增加而降低。游离前列腺特异抗原百分比与活检阳性概率之间存在显著关系;在该队列中,游离前列腺特异抗原百分比低(≤10%)的患者患癌概率(63±9%)高于游离前列腺特异抗原百分比高(≥26%)的患者(概率2±3%)。
游离前列腺特异抗原百分比可用于辅助鉴别总前列腺特异抗原在4.0至10.0 ng/mL之间男性的前列腺癌与良性疾病。需要开展大型前瞻性多中心试验,以制定一致的建议并确定合适的切点和风险概率,同时控制总前列腺特异抗原、前列腺体积、年龄和活检史。